1
|
Pinelli V, Christophe L, Cheron N, Morin S, Gilis L, Heuze C, Clerc-Renaud D, Morotti L, Vilhet B, Bissardon S, Magro L. [Pre-, per- and post-allogeneic haematopoietic stem cell transplant rehabilitation (Atelier SFGM-TC)]. Bull Cancer 2024:S0007-4551(24)00217-0. [PMID: 38981828 DOI: 10.1016/j.bulcan.2024.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 04/29/2024] [Accepted: 05/05/2024] [Indexed: 07/11/2024]
Abstract
Allogeneic transplantation of haematopoietic stem cells is still the only curative treatment for certain haematological malignancies. This treatment can be responsible for a number of side-effects, leading to multiple and interdependent physical and psychological deficiencies that affect patients' quality of life and social participation, and can be experienced as a handicap, sometimes for several years after the transplant. For several years now, the integration of post-transplant rehabilitation pathways has been becoming more widespread, and initiatives to provide multidisciplinary care at an increasingly early stage are being studied. The aim of this early management is to improve the patient's overall functional state before, during and after the transplant, in order to limit the impact of the treatment and ensure the quickest possible return to a life that is as satisfying as possible. The international literature and the experiments carried out throughout the French-speaking world describe heterogeneous practices. Based on this literature and experience, the aim of this study is to issue homogenous recommendations for good clinical practice and to identify areas for further research into pre-transplant, per-transplant and post-transplant rehabilitation of haematopoietic stem cells.
Collapse
Affiliation(s)
- Virgile Pinelli
- Clinique de l'Union, unité de préhabilitation et oncoréhabilitation, boulevard Ratalens, 31240 Saint-Jean, France.
| | - Laure Christophe
- Service d'oncoréhabilitation, hôpital Henry-Gabrielle, Saint-Genis-Laval, hospices civils de Lyon, Lyon, France
| | - Nathalie Cheron
- Centre hospitalier de Bligny, service hématologie soins de suite, rue de Bligny 91640 Briis-sous-Forges, France
| | - Sarah Morin
- Hopital universitaire de Genève, service d'hématologie, rue Gabrielle-Perret-Gentil 4, 1211 Genève 14, Suisse
| | - Lila Gilis
- Service d'oncoréhabilitation, hôpital Henry-Gabrielle, Saint-Genis-Laval, hospices civils de Lyon, Lyon, France
| | - Candy Heuze
- Service d'hématologie, CHU de Rouen, 37, boulevard Gambetta, 76000 Rouen, France
| | - Dominique Clerc-Renaud
- Hopital universitaire de Genève, service d'hématologie, rue Gabrielle-Perret-Gentil 4, 1211 Genève 14, Suisse
| | - Laurence Morotti
- CHU Saint-Eloi, pôle des cliniques médicales, 80, avenue Augustin-Fliche, 34090 Montpellier, France
| | - Benoit Vilhet
- CHU Saint-Eloi, pôle des cliniques médicales, 80, avenue Augustin-Fliche, 34090 Montpellier, France
| | - Sandra Bissardon
- Institut de cancérologie et d'hématologie universitaire de Saint-Étienne, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France
| | - Leonardo Magro
- CHRU de Lille, service des maladies du sang, 2, avenue Oscar-Lambret, 59037 Lille cedex, France
| |
Collapse
|
2
|
Kuczmarski TM, Roemer L, Odejide OO. Depression in patients with hematologic malignancies: The current landscape and future directions. Blood Rev 2024; 65:101182. [PMID: 38402023 DOI: 10.1016/j.blre.2024.101182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 02/08/2024] [Accepted: 02/12/2024] [Indexed: 02/26/2024]
Abstract
Patients with hematologic malignancies experience high rates of depression. These patients are vulnerable to depression throughout the disease trajectory, from diagnosis to survivorship, and at the end of life. In addition to the distressing nature of depression, it has substantial downstream effects including poor quality of life, increased risk of treatment complications, and worse survival. Therefore, systematic screening for depression and integration of robust psychological interventions for affected patients is crucial. Although depression has been historically studied mostly in patients with solid malignancies, research focusing on patients with hematologic malignancies is growing. In this article, we describe what is known about depression in patients with hematologic malignancies, including its assessment, prevalence, risk factors, and implications. We also describe interventions to ameliorate depression in this population. Future research is needed to test effective and scalable interventions to reduce the burden of depression among patients with blood cancers.
Collapse
Affiliation(s)
| | - Lizabeth Roemer
- Department of Psychology, University of Massachusetts Boston, USA
| | - Oreofe O Odejide
- Division of Population Sciences, Dana-Farber Cancer Institute, Boston, USA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, USA.
| |
Collapse
|